Standard Biotools (LAB) Common Equity (2010 - 2026)

Standard Biotools (LAB) has 17 years of Common Equity data on file, last reported at $561.1 million in Q1 2026.

• On a quarterly basis, Common Equity rose 23.43% year-over-year to $561.1 million in Q1 2026; TTM through Mar 2026 was $561.1 million, a 23.43% increase from a year earlier, with the FY2025 full-year figure at $424.3 million, down 10.05% from the prior year.
• Common Equity for Q1 2026 stood at $561.1 million, up from $424.3 million in the prior quarter.
• Over the last five years, Common Equity for LAB reached as high as $577.3 million in Q1 2024 and fell as low as -$148.1 million in Q4 2023.
• Historically, Common Equity has averaged $215.5 million across 5 years, with a median of $399.7 million in 2025.
• Across the five-year window, Common Equity tumbled 539.35% in 2023 and jumped 694.23% in 2024, its largest moves.
• Year by year, Common Equity stood at -$81.5 million in 2022, then sank by 81.73% to -$148.1 million in 2023, then surged by 418.62% to $471.7 million in 2024, then retreated by 10.05% to $424.3 million in 2025, then jumped by 32.25% to $561.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $561.1 million in Q1 2026, $424.3 million in Q4 2025, and $399.7 million in Q3 2025.